

ORIGINAL ARTICLE

Blood Pressure Response to Azilsartan in Hypertensive Patients

Praveen Kumar Chaudhary, V.K Bhalla

Department of General Medicine, Rajshree Medical Research Institute, Bareilly, U.P, India

ABSTRACT:

Background: Azilsartan is a novel angiotensin receptor blocker (ARB) being created for hypertension treatment. The primary point of this article is to assess the viability, wellbeing, and clinical part of azilsartan in hypertension patients. **Materials and Methods:** Total 70 hypertensive adults were incorporated into this examination. Parameters examined were age, indications, signs, examinations assuming any. All hypertensive grown-ups treated with Azilsartan 40 mg; alongside blood pressure response from day 1, day 8 and day 30 were noted. The essential endpoint was change in trough facility diastolic blood pressure (DBP) at week 8. **Result:** Male to Female proportion of 41 : 29 and the age extending from 30 years to 65 years with mean age of 46.12 years. The commonest side effect was headache in took after by giddiness and weakness. Day 1 mean Systolic Blood weight was 162.31 mm Hg and mean Diastolic Blood weight was 94.54 mm Hg, after treatment with Azilsartan the mean Systolic Blood Pressure on day 8 was 140.22 mm Hg and mean Diastolic Blood pressure was 86.20 mm Hg, and day 30 mean systolic Blood weight was 130.45 mm Hg and mean Diastolic Blood weight was 83.73 mm Hg. **Conclusion:** Azilsartan medoxomil is a sheltered and powerful with a remarkable pharmacologic profile contrasted and different operators, including impeded angiotensin-II sort 1 (AT1) receptor separation rates and enhanced receptor specificity.

Keywords: Azilsartan medoxomil, angiotensin receptor blocker, hypertension, blood pressure.

Corresponding author: Dr. V.K Bhalla, Department of General Medicine, Rajshree Medical Research Institute, Bareilly, U.P, India

This article may be cited as: Chaudhary PK, Bhalla VK. Blood Pressure Response to Azilsartan in Hypertensive Patients. J Adv Med Dent Scie Res 2017;5(8):20-23.

Access this article online	
<p>Quick Response Code</p> 	Website: www.jamdsr.com
	DOI: 10.21276/jamdsr.2017.5.7.07

Introduction:

Hypertension is an essential hazard factor for cardiovascular infection, and strict blood pressure (BP) control is basic from the point of view of counteractive action of cardiovascular sickness.¹ It is assessed that around half of patients on antihypertensive treatment are insufficiently overseen as far as their office BP, featuring the requirement for stricter BP control to avoid unfavorable sequelae.^{2,3} Strict BP control more than 24 h, including the evening time and early morning hours, is urgent, as the normal BP level more than 24 h, nighttime and early morning BP are all the more intently connected with target organ harm and cardiovascular occasions than office BP.⁴

In spite of advances in analytic and treatment modalities, hypertension remains a common therapeutic condition, influencing more than 27 % of the grown-up populace, a number anticipated that would ascend to almost 34 % by the year 2021. It is a noteworthy hazard factor for cardiovascular illness dismalness and mortality, including stroke, heart failure, and renal disease. Numerous examinations have exhibited the capacity of different

pharmacologic treatment regimens to diminish major cardiovascular occasion rates.⁵ Despite this confirmation, satisfactory control of blood pressure (BP) remains poor.⁶ Pharmacologic specialists that constrict the activities of the renin-angiotensin-aldosterone framework (RAAS) involve a standout amongst the most mainstream antihypertensive procedures for patients with hoisted BP.⁷ These incorporate angiotensin-changing over compound inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), coordinate renin inhibitors, and aldosterone rivals. ARBs lessen the activity of angiotensin-II by authoritative to and hindering the angiotensin-II sort 1 (AT1) receptor, prompting a dosage subordinate decline in fringe resistance, diminishment in vascular smooth muscle contraction, and decreased amalgamation and impacts of aldosterone on the kidney.⁸ Azilsartan medoxomil is a prodrug that is hydrolyzed inside the gastrointestinal tract to azilsartan before as well as amid assimilation. It is basically identified with candesartan except for a concoction change that builds the lipophilicity of azilsartan medoxomil and conceivably enhances its oral bioavailability. Preclinical examinations have demonstrated that azilsartan may have conceivably advantageous impacts

on cell systems of cardiometabolic illness and on insulin activity that could include something other than barricade of AT1 receptors or potentially decrease in blood pressure.⁹

An assortment of potential pleiotropic impacts with azilsartan medoxomil or azilsartan have been illustrated, possibly supporting its examination for treating accompanying scatters in patients with hypertension.¹⁰ These incorporate a measurement subordinate concealment of increments in plasma glucose levels following an oral glucose resilience test, enhanced insulin affectability, diminished epididymal fat tissue weight, concealment of plasminogen activator inhibitor sort 1 (PAI-1), and a dosage subordinate decrease in myocardial infarction.^{14–17} Minimal distributed information exist on the pharmacokinetic properties of azilsartan medoxomil, which is quickly hydrolyzed to azilsartan, as it is not perceptible in human plasma .

The present article depicts the BP-bringing down measurements reaction relationship of the AZL tablet definition in patients with fundamental hypertension.

Materials and Methods:

The study population consisted of 70 men and women aged 30-65 years and more established with mellow to direct uncomplicated fundamental hypertension (DBP ≥95 and ≤114 mm Hg. For incorporation, members were required to suspend their present antihypertensive medication(s), assuming any, 2 weeks before randomization. Clinical research facility assessments must be inside the reference ranges for the testing lab.

The principle prohibition criteria were SBP >180 mm Hg; a diminishing of ≥8 mm Hg in center DBP between the begin of the randomization visit; hypersensitivity to ARBs; grade 3/4 hypertensive retinopathy; clinically significant history of cardiovascular illness (eg, atrial fibrillation or flutter); auxiliary hypertension of any etiology; history of collagen vascular disorder inside the previous 5 years; direct to extreme renal dysfunction; history of medication or liquor mishandle ; dynamic liver disease; or jaundice. Pregnant or lactating ladies were likewise rejected. Barred pharmaceuticals included diuretics, vasodilators, thiazolidinediones, tricyclic antidepressants, lithium, monoamine oxidase inhibitors, phenothiazines, diet medicines, amphetamines or their subordinates, incessant utilization of common cold medication, or nonsteroidal anti-inflammatory drugs, including ibuprofen or cyclooxygenase inhibitors.

Table 2: BP in response to Azilsartan 40 mg

BP (mm Hg)	Day 1	After 1 week	After 1 month
Systolic	162.31	140.22	130.45
Diastolic	94.54	86.20	83.72

Amid the examination time frame, all patient got the appointed investigation sedate once day by day earlier or after breakfast. Patients received doasge of azilsartan 40mg daily for a month. Patients were surveyed by means of estimations of sitting BP and heartbeat rate and by means of physical examinations at center visits each week. Sitting BP was measured by the examiner no less than three times at 1- or 2-minute interims at trough utilizing a computerized or manual BP screen, and the mean estimation of two stable successive BP estimations was utilized for investigation. Patients took the investigation drug 1h after the begin of the estimations in the morning, and after the culmination of estimations on the next day. Amid the time of estimation, patients were told to abstain from taking bath, taking an evening nap, performing exercise and expending liquor and caffeine-containing nourishment/drinks.

The underlying Blood pressure was noted on day 1, at that point in this manner the Blood pressure was noted after week and after month were likewise noted, alongside any symptoms.

Result:

The commonest side effect was headache in took after by giddiness and weakness. Day 1 mean Systolic Blood weight was 162.31 mm Hg and mean Diastolic Blood weight was 94.54 mm Hg, after treatment with Azilsartan the mean Systolic Blood Pressure after week was 140.22 mm Hg and mean Diastolic Blood presure was 86.20 mm Hg, and after month mean systolic Blood weight was 130.45 mm Hg and mean Diastolic Blood weight was 83.72 mm Hg.

Table 1: Demographic details of patients

Variables	Number
Age (years)	46.12±5.2
Gender	
Male	41
Females	29
Weight (kg)	27.6±4.3
BMI (kg m ²)	
Symptoms	
Headache	26
Weakness	13
Giddiness	19
Body pain	7
Neck pain	5

Discussion:

Azilsartan, a novel angiotensin II type 1 (AT1) receptor blocker (ARB), was affirmed by administrative specialists for treatment of hypertension and is the eighth ARB to show up on the clinical market.¹¹ Like different ARBs, azilsartan is very specific for AT1 receptors and has more than a 10,000-fold more noteworthy proclivity for AT1 versus AT2 receptors. In the same way as other different ARBs, azilsartan can likewise work as an opposite agonist and hinder AT1 receptor flagging that may happen even without angiotensin II. In light of clinical investigations directed to date, azilsartan has all the earmarks of being described by a better capacity than control 24 h systolic blood pressure with respect to other broadly utilized ARBs.

In an examination, Khan et al. report that azilsartan can decrease renal and cardiovascular damage in the unexpectedly hypertensive stout rodent.¹² Since the principle purpose behind endorsing ARBs and other antihypertensive medications is to control blood pressure and decrease the hazard for target organ harm, the discoveries of Khan et al. are of potential clinical intrigue. Preclinical investigations have shown that azilsartan may have possibly useful impacts on cell components of cardiometabolic disease and on insulin activity that could involve more than simply blockade of AT1 receptors as well as decrease in blood weight. An investigation detailed that azilsartan is a pleiotropic ARB with antiproliferative impacts in refined vascular cells that may not entirely rely upon AT1 receptor barricade.¹³ Moreover, in examines in T3-L1 cells, azilsartan has been found to advance adipocyte separation and fortify articulation of qualities encoding peroxisome proliferator enacted receptors (PPAR) α and δ , leptin, adiponectin, and adiponectin more than valsartan.¹⁴

In our examination we had 70 patients of Hypertension who were treated with Azilsartan 40 mg. Among them 41 (58%) were male and 29 (42%) were female which is comparatively revealed by M K Singh¹⁵ et al 51% to 49%, Sathya et al¹⁶ 50.7% to 50.3% and William et al¹⁷ announced 54% to 46%. The age of the patients was 30 years to 65 years with Mean Age of 46.12 ± 5.2 years however M K Singh et al¹⁷ had patients age going from 20 years to >70 years. However, William et al¹⁷ had Mean age of 52 years in their ponder gathering. The commonest side effect of introduction was cerebral pain/headache in patients took after by giddiness, weakness, body agonies and neck pains which are nonspecific yet have been accounted for correspondingly by William et al.¹⁷

The Mean Systolic blood pressure at introduction was 162.31 mm Hg and Mean Diastolic pulse was 94.54 mm of Hg, which is more than detailed by Gupta et al¹⁸ of systolic blood pressure of 128.8 mm Hg, yet like Yugoslavian cohort¹⁹ a standard systolic BP of 144.2 mmHg. After these patients were treated with day by day Azilsartan 40 mg the Mean systolic blood pressure on day 8 was 140.22 mm Hg and Mean Diastolic blood pressure was 86.20 mm Hg. What's more, on day 30 the Mean Systolic Blood pressure

was 130.55 mm Hg and Mean Diastolic Blood weight was 83.72 mm Hg like outcomes by Bakris et al.²⁰

Azilsartan incites impossible hostility of angiotensin II-prompted vascular compressions and opposite agonism against AT1. The high-partiality and tight restricting properties of azilsartan are relied upon to prompt intense and durable antihypertensive impacts in preclinical and clinical settings. The scope of measurements chose for this examination was resolved to be sheltered and all around endured.

The general occurrence of unfriendly impacts was not measurement reliant and all dosages were very much endured. The wellbeing profile is predictable with past information for different ARBs and was affirmed.

Our investigation must be seen with regards to its confinements. Initial, a noteworthy restriction of all the included trials is their brief span of study which makes it hard to catch long haul advantages and reactions related with azilsartan treatment. Second, the conceivable part of azilsartan in averting mortality and cardiovascular dismalness was not evaluated.

Conclusion:

Azilsartan 40 mg gave fast huge diminishments in DBP and SBP in patients with mild to moderate uncomplicated fundamental hypertension. Azilsartan another angiotensin receptor (ARB) blocker has better clinical Blood pressure lowering impacts contrasted down with different ARBs with great resilience.

References:

1. Kearney PM, Whelton M, Reynolds K, et al., Global burden of hypertension: analysis of worldwide data, *Lancet*, 2005;365:217–23.
2. Chobanian AV, Bakris GL, Black HR, et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, *JAMA*, 2003;289:2560–72.
3. Mancia G, De Backer G, Dominiczak A, et al., 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension, *J Hypertens*, 2007;25:1751–62.
4. Czernichow S, Zanchetti A, Turnbull F, et al., The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials, *J Hypertens*, 2011;29:4–16.
5. Turnbull F, Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials, *Lancet*, 2003;362:1527–35.
6. Egan BM, Zhao Y, Axon RN, US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008, *JAMA*, 2010;303:2043–50.
7. Elliott WJ, Plauschinat CA, Skrepnek GH, et al., Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies, *J Am Board Fam Med*, 2007;20:72–80.

8. Kohara Y, Kubo K, Imamiya E, et al., Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres, *J Med Chem*, 1996;39:5228–35.
9. Ojima M, Igata H, Tanaka M, et al., In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies, *J Pharmacol Exp Ther*, 2011;336:801–8.
10. French C, Tarikuz Zaman AKM, Sobel BE, The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques, *J Cardiovasc Pharmacol*, 2011;58:143–8.
11. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. *Vasc Health Risk Manag*. 2012;8: 133–43.
12. Khan MA, Neckar J, Cummings B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. *Cardiovasc Drugs Ther* 2014;28: this issue.
13. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. *J Hypertens*. 2011;29:2476–83.
14. Araújo AA, Varela H, Brito GA, Medeiros CA, Araújo Lde S, do Nascimento JH, et al. Azilsartan increases levels of IL-10, down-regulates MMP-2, MMP-9, RANKL/RANK, Cathepsin K and Up-regulates OPG in an experimental periodontitis model. *PLoS One*. 2014;9:e96750.
15. Manoj Kumar Singh, Bhaskar Singamsetty, Jithendra Kandati, An epidemiological study of prevalence of hypertension and its risk factors in a rural community of Nellore, Andhra Pradesh, India Singh MK et al. *Int J Community Med Public Health*. 2016;3:3408-3414.
16. Sathya Prakash Manimunda, Attayuru Purushottaman Sugunan, Vivek Benegal, Nagalla Balakrishna, Mendu Vishnuvardhana Rao, Kasturi S Pesala Association of hypertension with risk factors and hypertension related behaviour among the aboriginal Nicobarese tribe living in Car Nicobar Island, India Year: *Indian J Med Res*. 2011; 133:3:287-293.
17. William B. White, Michael A. Weber, Domenic Sica, George L. Bakris, Alfonso P, Charlie C, Stuart K. Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. *Hypertension*. 2011;57:413-420.
18. Gupta R, Al-Odat NA, Gupta VP. Hypertension epidemiology in India: meta-analysis of 50 year prevalence rates and blood pressure trends. *J Hum Hypertens*. 1996; 10: 465–472.
19. Nedeljkovic SI, Ostojic MC, Vukotic MR, Grujic MZ. Recent trends in cardiovascular disease and risk factors: Yugoslavia. In: Toshima H, Koga Y, Blackburn H (eds). *Lessons for Science from Seven Countries Study*. Springer-Verlag: Tokyo. 1994, pp 75–92.
20. Bakris GL, Sica D, Weber MA, White WB, Roberts A, Perez A, et al. The comparative effects of Azilsartan medoxomil and Olmesartan on ambulatory and clinical blood pressure. *J Clin Hyp*. 2011;13:81-88.

Source of support: Nil

Conflict of interest: None declared

This work is licensed under CC BY: *Creative Commons Attribution 3.0 License*.